Table 1. Baseline characteristics of patients in anlotinib group and TACE group.
| Variables | n (%) | P | |
| Anlotinib (N=27) |
TACE (N=36) |
||
| TACE, transcatheter arterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; PVTT, portal vein tumor thrombosis. | |||
| Age [median (range)] (year) | 55 (40−73) | 56 (32−84) | 0.50 |
| Sex | 1.00 | ||
| Male | 23 (85.19) | 30 (83.33) | |
| Female | 4 (14.81) | 6 (16.67) | |
| Child-Pugh score | 0.18 | ||
| A5/6 | 25 (92.59) | 36 (100) | |
| B7 | 2 (7.41) | 0 (0) | |
| ECOG performance score | 0.02 | ||
| 0 | 25 (92.59) | 25 (69.44) | |
| 1 | 2 (7.41) | 11 (30.56) | |
| BCLC stage | 0.11 | ||
| A | 23 (85.19) | 22 (61.11) | |
| B | 2 (7.41) | 5 (13.89) | |
| C | 2 (7.41) | 9 (25.00) | |
| HBV infection | 0.07 | ||
| Positive | 24 (88.89) | 25 (69.44) | |
| Negative | 3 (11.11) | 11 (30.56) | |
| Cirrhosis | 0.07 | ||
| Yes | 24 (88.89) | 25 (69.44) | |
| No | 3 (11.11) | 11 (30.56) | |
| Extrahepatic metastasis | 0.25 | ||
| Yes | 0 (0) | 3 (8.33) | |
| No | 27 (100) | 33 (91.67) | |
| No. of intrahepatic lesions | 0.37 | ||
| 1 | 20 (74.07) | 30 (83.33) | |
| >1 | 7 (25.93) | 6 (16.67) | |
| Microvascular invasion | 1.00 | ||
| Yes | 24 (88.89) | 33 (91.67) | |
| No | 3 (11.11) | 3 (8.33) | |
| PVTT | <0.01 | ||
| VP1 | 4 (14.81) | 0 (0) | |
| VP2 | 2 (7.41) | 0 (0) | |
| VP3 | 0 (0) | 8 (22.22) | |
| No | 21 (77.78) | 28 (77.78) | |
| Differentiation | 0.01 | ||
| Grade 1−2 | 7 (25.93) | 21 (58.33) | |
| Grade 3−4 | 20 (74.07) | 15 (41.67) | |
| Capsule | 1.00 | ||
| Complete | 2 (7.41) | 2 (5.56) | |
| Uncomplete | 25 (92.59) | 34 (94.44) | |
| Surgical margin | − | ||
| Positive | 0 (0) | 0 (0) | |
| Negative | 27 (100) | 36 (100) | |